Off-label medications in the treatment of hospitalized children with atopic dermatitis

Introduction Off-label prescribing is defined as using medications outside conditions of the marketing authorisation including their licensed indications, dosage, age and route. Atopic dermatitis (AD) is the most common chronic skin condition in children which can be related to a high level of off-label prescribing. Aim To investigate the frequency of off-label prescribing and the medications involved in relation to indications and age in paediatric patients hospitalized for atopic dermatitis in a paediatric dermatology ward in 2019. Material and methods One hundred and seventy-five consecutive discharge letters of patients were analysed regarding gender, age and medications used during hospital stay and prescribed on discharge. Each medication was checked against the licensed age and indications. Results Altogether 564 medications were prescribed, including 289 topical and 275 systemic ones with 278 prescribed off-label (49.1%). Out of 289 topical medications, 113 (39.1%) were prescribed off-label regarding indications and 34 (11.76%) regarding the age of the patients. In the systemic medications group, 96 (34.53%) were prescribed off-label as AD was not a registered indication and 35 (12.73%) as the age of the patients was outside the marketing authorization. The most frequent medications prescribed off-label were antihistamines, antibiotics and corticosteroids. Conclusions Prescribing off-label in paediatric population is a common practice. Both topical and systemic medications are frequently used in AD patients off-label, therefore doctors should be familiar with the pitfalls of prescribing beyond the licensed indications and age.

[1]  A. Bailey,et al.  Hydroxyzine Use in Preschool Children and Its Effect on Neurodevelopment: A Population-Based Longitudinal Study , 2022, Frontiers in Psychiatry.

[2]  A. Miklos,et al.  Off-Label Medication: From a Simple Concept to Complex Practical Aspects , 2021, International journal of environmental research and public health.

[3]  D. Morrell,et al.  Current Perspectives on the Systemic Management of Atopic Dermatitis , 2021, Journal of asthma and allergy.

[4]  J. Ring,et al.  ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[5]  S. Feldman,et al.  Comparing prescribing patterns for topical corticosteroids based on their FDA indication by age , 2020, Pediatric dermatology.

[6]  J. Treat,et al.  Treatment of severe pediatric atopic dermatitis with methotrexate: A retrospective review , 2019, Pediatric dermatology.

[7]  K. França,et al.  Controversies in off‐label prescriptions in dermatology: the perspective of the patient, the physician, and the pharmaceutical companies , 2018, International journal of dermatology.

[8]  E. Weisshaar,et al.  Oral H1 antihistamines as 'add-on' therapy to topical treatment for eczema. , 2019, The Cochrane database of systematic reviews.

[9]  A. Muraro,et al.  Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[10]  S. Feldman,et al.  Prescriptions for atopic dermatitis: oral corticosteroids remain commonplace , 2018, The Journal of dermatological treatment.

[11]  F. Plessow,et al.  Increased attention‐deficit/hyperactivity symptoms in atopic dermatitis are associated with history of antihistamine use , 2018, Allergy.

[12]  M. Lebwohl,et al.  A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis , 2017, Journal of the American Academy of Dermatology.

[13]  J. Aronson,et al.  Unlicensed and off‐label uses of medicines: definitions and clarification of terminology , 2017, British journal of clinical pharmacology.

[14]  M. Lebwohl,et al.  Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies. , 2017, The journal of allergy and clinical immunology. In practice.

[15]  J. C. Jaworski,et al.  Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis , 2016, BMC Pediatrics.

[16]  Ian C. Ellul,et al.  Maltese prescribers use of off-label and unlicensed medicines in children: perceptions and attitudes , 2016, International Journal of Clinical Pharmacy.

[17]  P. Schmid‐Grendelmeier,et al.  IgE responses to exogenous and endogenous allergens in atopic dermatitis patients under long‐term systemic cyclosporine A treatment , 2015, Allergy.

[18]  M. Hassali,et al.  Awareness, knowledge and views of off-label prescribing in children: a systematic review. , 2015, British journal of clinical pharmacology.

[19]  G. Morente,et al.  Oral Cyclosporine Weekend Therapy: A New Maintenance Therapeutic Option in Patients with Severe Atopic Dermatitis , 2015 .

[20]  T. Bieber,et al.  Off‐label prescriptions for atopic dermatitis in Europe , 2015, Allergy.

[21]  C. Lenk,et al.  Ethical and legal framework and regulation for off-label use: European perspective , 2014, Therapeutics and clinical risk management.

[22]  R. Fölster-Holst.  Management of atopic dermatitis: are there differences between children and adults? , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

[23]  M. Morais‐Almeida,et al.  Off-label prescribing for allergic diseases in children , 2014, The World Allergy Organization journal.

[24]  P. Jolliet,et al.  Off-label prescriptions: how to identify them, frame them, announce them and monitor them in practice? , 2013, Therapie.

[25]  W. Carr.  Topical Calcineurin Inhibitors for Atopic Dermatitis: Review and Treatment Recommendations , 2013, Pediatric Drugs.

[26]  H. Kokki,et al.  Off‐label and unlicensed drug prescribing in three paediatric wards in Finland and review of the international literature , 2009, Journal of clinical pharmacy and therapeutics.

[27]  G. Canonica,et al.  New oral H1 antihistamines in children: facts and unmeet needs , 2008, Allergy.

[28]  P. Hill,et al.  Off licence and off label prescribing in children: litigation fears for physicians , 2005, Archives of Disease in Childhood.

[29]  C. Meisner,et al.  ["Off-label" prescribing of drugs in the ambulatory care of children and adolescents]. , 2002, Deutsche medizinische Wochenschrift.

[30]  G. Breart,et al.  Off label and unlicensed drug use among French office based paediatricians , 2000, Archives of disease in childhood.

[31]  A. Finlay,et al.  Cyclosporine in severe childhood atopic dermatitis: a multicenter study. , 1996, Journal of the American Academy of Dermatology.